AU2177401A - Combination of riluzole and gabapentin and use thereof as medicine - Google Patents

Combination of riluzole and gabapentin and use thereof as medicine

Info

Publication number
AU2177401A
AU2177401A AU21774/01A AU2177401A AU2177401A AU 2177401 A AU2177401 A AU 2177401A AU 21774/01 A AU21774/01 A AU 21774/01A AU 2177401 A AU2177401 A AU 2177401A AU 2177401 A AU2177401 A AU 2177401A
Authority
AU
Australia
Prior art keywords
riluzole
gabapentin
medicine
combination
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU21774/01A
Inventor
Andrees Bohme
Christopher Henderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of AU2177401A publication Critical patent/AU2177401A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention concerns the combination of riluzole and gabapentin or one of their pharmaceutically acceptable salts and its use as medicine in particular for use in preventing and /or treating motor neuron disorders.
AU21774/01A 1999-11-24 2000-11-24 Combination of riluzole and gabapentin and use thereof as medicine Abandoned AU2177401A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9914765 1999-11-24
FR9914765A FR2801217B1 (en) 1999-11-24 1999-11-24 COMBINATION OF RILUZOLE AND GABAPENTINE AND ITS USE AS A MEDICINAL PRODUCT
PCT/FR2000/003272 WO2001037832A2 (en) 1999-11-24 2000-11-24 Combination of riluzole and gabapentin and use thereof as medicine

Publications (1)

Publication Number Publication Date
AU2177401A true AU2177401A (en) 2001-06-04

Family

ID=9552471

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21774/01A Abandoned AU2177401A (en) 1999-11-24 2000-11-24 Combination of riluzole and gabapentin and use thereof as medicine

Country Status (10)

Country Link
EP (1) EP1235573B1 (en)
JP (1) JP4928697B2 (en)
AT (1) ATE245421T1 (en)
AU (1) AU2177401A (en)
DE (1) DE60004093T2 (en)
DK (1) DK1235573T3 (en)
ES (1) ES2198369T3 (en)
FR (1) FR2801217B1 (en)
PT (1) PT1235573E (en)
WO (1) WO2001037832A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
US20060264509A1 (en) * 2003-03-21 2006-11-23 Fraser Matthew O Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators
KR100742001B1 (en) * 2003-03-21 2007-07-23 다이노젠 파마세우티컬스, 인코포레이티드 Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
EP2879678B1 (en) * 2012-07-31 2023-03-01 Yeda Research and Development Co. Ltd. Enoxacin for treating amyotrophic lateral sclerosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
FR2688138B1 (en) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa APPLICATION OF AMINO-2 TRIFLUOROMETHOXY-6 BENZOTHIAZOLE TO OBTAIN A MEDICINE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS.
FR2702148B1 (en) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application of anti-convulsants in the treatment of neuro-AIDS.
WO1999008670A1 (en) * 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage

Also Published As

Publication number Publication date
FR2801217B1 (en) 2002-12-06
EP1235573B1 (en) 2003-07-23
WO2001037832A2 (en) 2001-05-31
ES2198369T3 (en) 2004-02-01
ATE245421T1 (en) 2003-08-15
PT1235573E (en) 2003-11-28
WO2001037832A3 (en) 2002-03-21
EP1235573A2 (en) 2002-09-04
DE60004093D1 (en) 2003-08-28
FR2801217A1 (en) 2001-05-25
JP4928697B2 (en) 2012-05-09
DK1235573T3 (en) 2003-11-24
DE60004093T2 (en) 2004-06-03
JP2003514858A (en) 2003-04-22

Similar Documents

Publication Publication Date Title
YU37602A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
GB0108592D0 (en) Therapeutic agents
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
PL310475A1 (en) Application of anticonvulsants in treating neuro-aids diseases
SI1594833T1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
AU2002339128A1 (en) Use of reelin, gas6, and protein s in the treatment of neural disorders
BR9808606A (en) Materials and methods for treating diseases with ribozymes
AU5636300A (en) Use of creatine or creatine analogs for the prevention and treatment of transmissible spongiform encephalopathies
AU2002247973A1 (en) Use of epigallocatechin-3-gallate or its derivatives in the prevention and treatment of neurodegenerative diseases
WO2001039792A3 (en) The use of caspase 9 inhibitors to treat ocular neural pathology
AU2177401A (en) Combination of riluzole and gabapentin and use thereof as medicine
EP1152762B8 (en) Use of desoxypeganine in the treatment of alzheimer's dementia
AU1278600A (en) Novel therapeutic application of nicergoline
WO2003092701A3 (en) Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders
IL143280A0 (en) Use of riluzole for treating acoustic traumas
GB9802542D0 (en) New use
MXPA02003731A (en) Novel fusidic acid derivatives.
AU1569700A (en) Novel therapeutic application of low molecular weight heparin
IL125660A0 (en) Pharmaceutical composition comprising 2-(3,4-dimethoxycinnamoyl)-aminobenzoic acid for the aminobenzoic acid for the treatment or prevention of restenosis and its manufacture
AU2002224253A1 (en) Medicine based on diethylaminoethanol derivatives and its use for the prevention and treatment of inflammatory and degenerative diseases
WO2004091522A3 (en) Method for treating neurodegenerative disorders
FR2786099B1 (en) NEW THERAPEUTIC APPLICATION OF 1,6-DIMETHYL-8BETA- HYDROXYMETHYL-10ALPHA-METHOXYERGOLINE
AU6331199A (en) Oxazolidine derivatives for the treatment and prevention of metabolic bone disorders
CA2409379A1 (en) Use of riluzole or its salts for preventing and treating adrenoleukodystrophy
UA32314A (en) Method for treating necrotic pancreatitis

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase